Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 601–700 of 1,001
The Resurgence of Hallucinogen Drugs in Clinical Research
Rivera-Garcia, M. T., & Cruz, S. L. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000108 · Cited by 16
“In addition, administering two doses of psilocybin (10 and 25 mg) to patients with treatment-resistant depression significantly reduced depressive symptoms throughout 6-months 41 .”
BackgroundThe possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
“Clinical trial NCT03429075 led by Carhart-Harris demonstrated no significant differences between the antidepressant effect induced by two doses of psilocybin (25 mg) separated with a 3-week interval and a daily, 6-week treatment with escitalopram [148].”
BackgroundResultAssessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
“Although the 2021 study by Carhart-Harris et. al [14]. was not designed as a non-inferiority trial, and would have been under-powered as such, it is notable that the study found no difference in primary outcome between the psilocybin treatment and treatment-as-usual with a known efficacious and…”
BackgroundResultJohansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“Other than the recent randomised controlled trial comparing psilocybin-assisted psychotherapy and escitalopram [17], no trial has utilised an active control.”
BackgroundMethodResultInfluentialFragile promise of psychedelics in psychiatry
Lemarchand, C., Chopin, R., Paul, M., Braillon, A., Cosgrove, L., Cristea, I., Fried, E. I., Turner, E. H., & Naudet, F. (2024) · BMJ · doi:10.1136/bmj-2024-080391 · Cited by 11
A Critical View on New and Future Antidepressants
Serretti, A. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1145 · Cited by 13
“Therefore a number of studies have been performed [42-44].”
BackgroundModulation of serotonin transporter expression by escitalopram under inflammation
Mena, S., Cruikshank, A., Best, J. A., Nijhout, H. F., Reed, M. C., & Hashemi, P. (2024) · Communications Biology · doi:10.1038/s42003-024-06240-3 · Cited by 13
“It is dif fi cult to reconcile highly variable clinical data, but studies report patients response to escitalopram to be only 10 – 20% higher than placebo 91,92 , which is comparable to all other antidepressants, including psilocybin 93 .”
ResultPsychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 12
Sutherland, I., Ho, M., & Croarkin, P. E. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0082 · Cited by 12
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
Destoop, M., Mohr, P., Butlen‐Ducuing, F., Kéri, P., Samochowiec, J., Picker, L. D., Fiorillo, A., Kuypers, K. P. C., & Dom, G. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1806 · Cited by 11
Psilocybin for disorders of consciousness: A case-report study
Cardone, P., Nùñez, P., Alnagger, N., Martial, C., van der Lande, G., Sandell, R., Carhart-Harris, R. L., & Gosseries, O. (2025) · Clinical Neurophysiology · doi:10.1016/j.clinph.2025.02.264 · Cited by 13
Self-citationAmaev, A., Song, J., Kambari, Y., Carmona-Torres, E., Abdolizadeh, A., Ueno, F., Koizumi, T., Strafella, A. P., Husain, M. I., Graff‐Guerrero, A., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.03.022 · Cited by 11
Łysik, A., Logoń, K., Szczygieł, A., Wołoszczak, J., Wrześniewska, M., & Leszek, J. (2025) · GeroScience · doi:10.1007/s11357-025-01615-8 · Cited by 11
Psilocybin Dispensaries and Online Health Claims in Canada
Matsukubo, J., Dickson, S., Xiao, J., Friesen, E. L., Solmi, M., Fiedorowicz, J. G., Fischer, B., & Myran, D. T. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2853 · Cited by 15
Ramirez, C., Alayine, G. A., Akafia, C. S. K., Adichie, K., Watts, D., Galdamez, Y., Harding, L., & Allsop, S. A. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1554156 · Cited by 13
Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises
Harding, R., Singer, N., Wall, M. B., Hendler, T., Erritzøe, D., Nutt, D. J., Carhart-Harris, R. L., & Roseman, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03035-8 · Cited by 12
Self-citationAre we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
Qureshi, O., Cowley, J., Pegg, A., Cooper, A. J., Gordon, J., Brady, C., Belli, A., Butterworth, S., Upthegrove, R., Andrews, N., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70138 · Cited by 13
“Initially, the investigated indications were centred around depression and anxiety (Carhart-Harris et al., 2021; Griffiths et al., 2016; Holze et al., 2023; Reckweg et al., 2023; Ross et al., 2016), but this has now expanded to conditions such as post-traumatic stress disorder, substance abuse…”
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Adeyinka, D. A., Forsyth, D., Currie, S., & Faraone, N. (2025) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2025.1585367 · Cited by 12
“…in depression, more research is needed to determine the safest and most eective dosing schedules for dierent individuals and conditions (Carhart-Harris et al., 2021; Carhart-Harris et al., 2021; Davis et al., 2021) which would help in the understanding of how often psilocybin can be…”
Psilocybin Conspectus: Status, Production Methods, and Considerations
Plotnik, L., Gibbs, G., & Graham, T. (2021) · International journal of medicinal mushrooms · doi:10.1615/intjmedmushrooms.2021041921 · Cited by 11
Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice
Pędzich, B. D., Medrano, M., Buckinx, A., Smolders, I. J., & Bundel, D. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315284 · Cited by 12
Gray, J. C., Murphy, M. A., Carter, S. E., Johnson, M. W., Wolfgang, A. S., Roy, M. J., & Maples‐Keller, J. L. (2022) · Military Medicine · doi:10.1093/milmed/usac400 · Cited by 13
Argento, E., Omene, E., Jaeger, A. H., Kertes, A., Mitchell, K. A., Necyk, C., Thielking, P. D., & Lewis, E. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1197409 · Cited by 12
“The psychedelic-assisted therapy model has demonstrated both short and long-term improvements in MDD and PTSD in clinical trials utilizing psilocybin and MDMA—which, like ketamine, also promote alteration of brain network connectivity (Carhart-Harris et al., 2021; Davis et al., 2021; Mitchell et al., 2021; Gukasyan et…”
MethodTylš, F., Vejmola, Č., Koudelka, V., Piorecká, V., Kadeřábek, L., Bochin, M., Novák, T., Kuchař, M., Bendová, Z., Brunovský, M., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1152578 · Cited by 12
Psychedelic phenomenology and the role of affect in psychological transformation
Kochevar, C. (2023) · Phenomenology and the Cognitive Sciences · doi:10.1007/s11097-023-09943-w · Cited by 14
The safety of supported psilocybin use in Oregon
Smith, W., Sisti, D. A., & Appelbaum, P. S. (2024) · Nature Medicine · doi:10.1038/s41591-023-02727-4 · Cited by 12
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Song-Smith, C., Jacobs, E., Rucker, J., Saint, M., Cooke, J. E., & Schlosser, M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083595 · Cited by 12
Varty, G. B., Canal, C. E., Mueller, T. A., Hartsel, J. A., Tyagi, R., Avery, K., Morgan, M. E., Reichelt, A. C., Pathare, P., Stang, E. M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01961 · Cited by 12
Classic psychedelics and the treatment for alcoholism
Lodetti, G., de Bitencourt, R. M., & Rico, E. P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111129 · Cited by 17
Zhang, M., Yang, Y., Yang, Z., Wen, X., Zhang, C., Xiao, P., Wang, Y., Sun, J., Wang, H., & Wang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117049 · Cited by 12
Herrmann, Z. M., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B. S., Penn, A., Jain, R., Raison, C. L., Rajanna, B., & Jain, S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0030 · Cited by 12
“52,61,62 Furthermore, numerous controlled trials 38,63,64 and studies on naturalistic psychedelic use 65–68 have suggested a benefit to user well-being.”
Rahbarnia, A., Li, Z., & Fletcher, P. J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06474-9 · Cited by 13
“Drug effects have also been assessed at a later time when drug is no longer present (Griffiths et al. 2016; Carhart-Harris et al. 2018, 2021).”
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression
Nemeroff, C. B. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21121204 · Cited by 12
Existential feelings as a phenomenological framework for psychedelic therapy
Tijhuis, F. B., Coninx, S., & de Bruin, L. C. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2412195 · Cited by 10
“…clinical trials have shown significant antidepressant or anxiolytic effects of psychedelic therapy at various time scales (Agin-Liebes et al., 2020; Carhart-Harris et al., 2016, 2021; Davis et al., 2021; Gasser et al., 2014, 2015; Goodwin et al., 2022; Griffiths et al., 2016; Grob et al., 2011;…”
Godfrey, K., Weiss, B., Zhang, X., Spriggs, M. J., Peill, J. M., Lyons, T., Carhart-Harris, R. L., & Erritzøe, D. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104092 · Cited by 12
Self-citationYousefi, P., Lietz, M. P., O'Higgins, F., Rippe, R. C. A., Hasler, G., van Elk, M., & Enriquez‐Geppert, S. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06742-2 · Cited by 11
Lashgari, N., Khalaji, M., Rana, P., Badrabadi, F., Rahnama, M., Nasoori, H., Roudsari, N. M., Nia, M. M. K., & Shafaroodi, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05097-9 · Cited by 10
Klučková, T., Nikolič, M., Tylš, F., Viktorin, V., Vejmola, Č., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., et al. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00742-5 · Cited by 10
Psychedelics: The pathway to implementation in the European healthcare systems
Gründer, G., Mertens, L. J., Spangemacher, M., Meyer‐Lindenberg, A., & Jungaberle, H. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.007 · Cited by 11
Global mushroom market: Bioactive compounds of major species and biotechnology applications
Tavares, Y. V., Contato, A. G., & Conte-Junior, C. A. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2025.11.010 · Cited by 11
Global species diversity and distribution of the psychedelic fungal genus Panaeolus
Strauss, D., Ghosh, S. B., Murray, Z., & Gryzenhout, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16338 · Cited by 11
Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
Jones, G. M., Al‐Suwaidi, M., Castro‐Ramirez, F., McGuire, T. C., Mair, P., & Nock, M. K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1169692 · Cited by 10
Nicholas, C. R. N., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., & Brown, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0012 · Cited by 10
“Additional modifications of eligibility criteria (Table 1) were included to align with research findings 10,74,75 emergent since the initial conceptualization of the study and to increase accessibility and inclusiveness.”
Brockett, A. T., & Francis, N. A. (2024) · Journal of Neurophysiology · doi:10.1152/jn.00124.2024 · Cited by 12
Smith, F. N., Neill, J. C., & Wainwright, V. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221124117 · Cited by 13
“This is consistent with literature suggesting psilocybin leads to decreases in anxiety (Grob et al., 2011) and depression (Carhart-Harris et al., 2018, 2021) and increases in connectedness (Watts et al., 2017).”
BackgroundResultPsychedelic medicine at a crossroads: Advancing an integrative approach to research and practice
Gobbi, G., Inserra, A., Greenway, K. T., Lifshitz, M., & Kirmayer, L. J. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119388 · Cited by 12
Fissler, P., Vandersmissen, A., Filippi, M., Mavioğlu, R. N., Scholkmann, F., Karabatsiakis, A., & Krähenmann, R. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231164707 · Cited by 11
“While the results are promising, current evidence is based on qualitative studies, observational studies, uncontrolled interventional studies and a limited number of randomized-controlled clinical studies (Carhart-Harris et al., 2021; Galvão-Coelho et al., 2021).”
BackgroundMethodResultInfluentialExtended Difficulties Following the Use of Psychedelic Drugs: A Mixed Methods StudyPreprint
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., & McAlpine, R. G. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4487243 · Cited by 12
Self-citationNikolič, M., Mediano, P. A. M., Froese, T., Reydellet, D., & Páleníček, T. (2024) · medRxiv · doi:10.1101/2024.09.09.24313316 · Cited by 12
“The antidepressant effect of a psychedelic dose of psilocybin has a rapid onset and sustained duration (R. Carhart-Harris et al., 2021; Davis et al., 2021; Griffiths et al., 2016; Yu et al., 2022).”
BackgroundNadeem, Z., Parker, S., McGovern, H. T., Sebben, B., & Oestreich, L. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251346679 · Cited by 10
“In recent years, there has been a resurgence of interest in the potential therapeutic applications of psyche-delics for psychiatric disorders and symptoms, including post-traumatic stress disorder (PTSD), end-of-life anxiety, major depressive disorder (MDD), obsessive compulsive disorder (OCD), anxiety and substance u…”
InfluentialAvanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03556-4 · Cited by 10
“The ef fi cacy of PAT has also not been directly compared to available TRD treatments, though one RCT did compare PAT to escitalopram, a widely used fi rst-line pharmacotherapy, in a study that focused on non-TRD (i.e., responsive) MDD [20, 21].”
Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Davis, A. K., DellaCrosse, M. A., Sepeda, N. D., Levin, A. W., Cosimano, M. P., Shaub, H., Washington, T., Gooch, P. M., Gilead, S., Gaughan, S. J., et al. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00461 · Cited by 11
Wong, S., Meckling, G., Fabiano, N., Lee, S., Jones, B. D. M., Shorr, R., Dargél, A., Davis, A. K., Fiedorowicz, J. G., Solmi, M., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251372449 · Cited by 10
“21 Carhart-Harris et al. 22 found a decrease in suicidal ideation from PT compared to escitalopram treatment that was significantly different.”
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
Meikle, S. E., Carter, O. L., Liknaitzky, P., Johansen, L., Iyer, R., Strauss, N. H. M., Williams, M. L., Castle, D. J., & Rossell, S. L. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251377187 · Cited by 10
“While most studies in MDD and TRD populations have employed a single moderate-to-high dose of psilocybin, two have employed a two-dose protocol 13,15 and reported higher response rates.”
Bukovsky, D., Amaev, A., Song, J., Kyte, S., Carmona-Torres, E., Ueno, F., Luca, V. D., Strafella, A. P., Husain, M. I., Graff‐Guerrero, A., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111541 · Cited by 10
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 10
Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy
Thase, M. E. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.mulmdd3048sho · Cited by 9
Psychedelic Microdosing among Young Adults from Southern California
Harlow, A. F., Hendricks, P. S., Leventhal, A. M., & Barrington‐Trimis, J. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2313684 · Cited by 9
“…positive effects of larger psychedelic doses (combined with psychological support) of MDMA (Mitchell et al. 2021; Varker et al. 2021), psilocybin (Carhart-Harris et al. 2016, 2021; Griffiths et al. 2016; Grob et al. 2011; Ross et al. 2016), and LSD (Fuentes et al. 2020) on treatment of substance…”
Effect of oral tryptamines on the gut microbiome of rats—a preliminary study
Xu, M., Kiss, A. J., Jones, J. A., McMurray, M. S., & Shi, H. (2024) · PeerJ · doi:10.7717/peerj.17517 · Cited by 10
Psychothérapie assistée par psychédéliques (PAP) : le modèle genevois
Seragnoli, F., Thorens, G., Penzenstadler, L. E., Furtado, L., Buchard, A., Bachmann, S., Iuga, R., Khatcherian, E., Nowotarski, A., Sabé, M., et al. (2024) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2024.05.014 · Cited by 12
Herpers, J., Maximets, N., van Dongen, N. N. N., Zijlmans, J., & Vermetten, E. H. G. J. M. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2024.2378651 · Cited by 9
“Psi-locybin-AT is currently undergoing Phase 3 clinical trials with promising results for treatment-resistant depression (Carhart-Harris et al., 2021; Griffiths et al., 2016), whereas ketamine-AT, through the approval of esketamine, has already established a pre-cedent with its FDA approval in 2019…”
BackgroundHovmand, O. R., Madsen, M. K., Fisher, P. M., & Stenbæk, D. S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241269669 · Cited by 10
“…such as alcohol use disorder (Bogenschutz et al., 2015, 2022), obsessive-compulsive disorder (Moreno et al., 2006), anxiety, and depression (Carhart-Harris et al., 2016, 2021; Davis et al., 2021; Goodwin et al., 2022; Grob et al., 2011; Raison et al., 2023; Ross et al., 2016; von Rotz et…”
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Barstowe, A., & Kajonius, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424272 · Cited by 12
“The inert placebo in this case is the micro-crystalline cellulose (Carhart-Harris et al. 2021).”
Constantino, J. L., van Dalfsen, J. H., Massetti, S., Kamphuis, J., & Schoevers, R. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111251 · Cited by 10
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges
Ghaznavi, S., & Richter, S. G. (2025) · Drugs · doi:10.1007/s40265-025-02172-2 · Cited by 10
“Some trials have attempted to address the issue of a placebo by having a low dose of the drug as a comparator instead (e.g., 1 mg of psilocybin) [46, 49].”
Hendricks, P. S., Copes, H., Family, N., Williams, L., Luke, D. P., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211055855 · Cited by 10
“In a study comparing psilocybin to escitalopram for depression, Carhart-Harris et al. (2021) administered two doses of psilocybin over an approximately 6-week intervention period that included one 3-h in-person preparatory session, two in-person integration sessions, and six “debriefing” or…”
BackgroundResultThe Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 10
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 10
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
Importance of achieving rapid treatment response in major depressive disorder
Alva, G. (2023) · CNS Spectrums · doi:10.1017/s1092852923002213 · Cited by 12
“21,28,38 Esmethadone, a novel NMDA receptor antagonist, can provide improvements in as little as 4 days of treatment in patients for whom up to 3 ADTs failed, but its long-term efficacy is unknown.”
BackgroundWest, C. L., Imai, F., Bastos, G., Hornick, M. A., Rachmany, L., Duran, A., Nadeem, S., Ricci, D., Groves, A. M. R., Wargo, J. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.03.601959 · Cited by 9
The psychedelic escape from depression
Eisenstein, M. (2022) · Nature · doi:10.1038/d41586-022-02872-9 · Cited by 8
Safety pharmacology of acute mescaline administration in healthy participants
Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., & Liechti, M. E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16349 · Cited by 9
Blest‐Hopley, G., Pasculli, G., Ruffell, S., Tsang, W., Olateju, E., Pate, K. M., Kettner, H., Roseman, L., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1594307 · Cited by 8
Self-citationHewitt, T., Amaya, I. A., Beauté, R., Seth, A. K., Schmidt, T. T., & Schwartzman, D. J. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niaf020 · Cited by 13
Kartar, A. A., Horinouchi, T., Örzsik, B., Anderson, B., Hall, L., Bailey, D., Samuel, S., Beltran, N., Bouyagoub, S., Racey, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329411 · Cited by 12
Caraccio, M., Cheung, K., Mann, S. P., Bruce, L., Jacobs, E., Villiger, D., Sandbrink, J. D., Register, C., Hannikainen, I. R., Høeg, M. L., et al. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2532761 · Cited by 10
Askey, T., Allen-Ross, D., Luzyanin, D., Lasrado, R., Gilmour, G., Hunt, S. P., Tamagnini, F., Ahmed, M., Stephens, G. J., & Maiarù, M. (2026) · Communications Biology · doi:10.1038/s42003-026-10065-7 · Cited by 10
“Recent clinical interest has centered on psilocybin ’ s potential for treating major depression and related mood disorders 7 , such conditions commonly co-occur with chronic pain.”
García‐Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118720 · Cited by 9
A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness
Alnagger, N., Cardone, P., Martial, C., Perl, Y. S., Mindlin, I., Sitt, J. D., Roseman, L., Carhart-Harris, R. L., Nutt, D. J., Mallaroni, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202511780 · Cited by 9
Self-citationda Cruz, R. V. L., Costa, R. B. G. D. M., de Queiroz, G. M., Stojanovic, T., Moulin, T. C., & Leão, R. N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03852-7 · Cited by 11
“Supporting this view, psilocybin has demonstrated robust and prolonged antidepressant ef fi cacy in clinical trials, with symptom improvements persisting for up to 12 months in some patients and a favorable safety pro fi le [25 – 29].”
Singleton, S. P., Sevchik, B. L., Lahey, A., Cuijpers, P. J., Harrer, M., Jones, M. T., Nayak, S. M., Strain, E. C., Vandekar, S., Dworkin, R. H., et al. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00630-8 · Cited by 9
Psychedelics: A New Treatment Paradigm in Psychiatry?
Gründer, G. (2021) · Pharmacopsychiatry · doi:10.1055/a-1520-5020 · Cited by 8
“Researchers from Imperial College London documented a numerically, but not statistically, larger decrease in depression self-rating scale scores in 30 patients treated with psilocybin compared to 29 patients treated with the reference antidepressant escitalopram [3].”
ResultHalberstadt, A. L., Luethi, D., Hoener, M. C., Trachsel, D., Brandt, S. D., & Liechti, M. E. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06279-2 · Cited by 8
“For example, promising results have been reported in clinical trials evaluating psilocybin for depression (Carhart-Harris et al. 2021; Davis et al. 2021), existential distress (Griffiths et al. 2016; Ross et al. 2016), nicotine dependence (Johnson et al. 2014, 2017), and alcoholism (Bogenschutz et…”
IsHak, W. W., García, P., Pearl, R., Dang, J., William, C., Totlani, J., & Danovitch, I. (2023) · PubMed Central · Cited by 14
EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Holsboer, F., & Ising, M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2372-3549 · Cited by 9
“…Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point serendipity: their potential as antidepressants was discovered decades after their introduction as anesthetic (ketamine) or hallucino - genic psychedelic drugs [7, 8].”
Informed Consent in Psychedelic-Assisted Therapy
Bradberry, M. M., Appelbaum, P. S., & Gukasyan, N. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_559 · Cited by 8
Immersive exposure to simulated visual hallucinations modulates high-level human cognition
Greco, A., Rastelli, C., Ubaldi, A., & Riva, G. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103808 · Cited by 9
Hippocampal Zkscan4 confers resilience to chronic stress–induced depression-like behaviors
Gao, K., Yang, Y., Sun, X., Wang, J., Sun, X., Lu, T., Wang, L., Li, M., Yue, W., Liu, H., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2291 · Cited by 10
“Accumulating evidence indicates that classic serotonergic psy-chedelics (e.g., psilocybin) hold promise as rapid and sustained anti-depressants for both patients with MD and animal models primarily through Htr2a activation ( 56 – 58 ), although this is not supported by all studies ( 59 ).”
Roseby, W., Kettner, H., Roseman, L., Spriggs, M. J., Lyons, T., Peill, J., Giribaldi, B., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1580663 · Cited by 11
Self-citationLissemore, J. I., Chaiken, A., Cherian, K. N., Buchanan, D. M., Espil, F. M., Keynan, J. N., Sridhar, M., Rolle, C. E., Saggar, M., Keller, C. J., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00463-x · Cited by 9
“…LSD (lysergic acid diethyla-mide) and DMT (N,N-dimethyltryptamine), have shown utility in treating psychiatric disorders such as depression 25 and have shown acute effects on cortical oscillations and complexity in healthy adults, such as increases in global Lempel–Ziv complexity and…”
Future Pharmacotherapy for Bipolar Disorders: Emerging Trends and Personalized Approaches
Marano, G., Lisci, F. M., Boggio, G., Marzo, E. M., Abate, F., Sfratta, G., Traversi, G., Mazza, O., Pola, R., Sani, G., et al. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030042 · Cited by 8
“In one trial, psilocybin showed comparable effects to escitalopram, although the absence of a placebo arm limited efficacy conclusions [165].”
Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review
Brittain, N., Higgins, N., Barber, M., Choi, W., Carter, A., & Gardner, J. (2025) · Journal of Bioethical Inquiry · doi:10.1007/s11673-025-10454-3 · Cited by 8
“Positive outcomes from trials of PAT have been reported for the treatment of depression and post-traumatic stress disorder (PTSD) (Carhart-Harris et al. 2021; Mitchell et al. 2021).”
Pasquini, L., Vohryzek, J., Escrichs, A., Perl, Y. S., Ponce‐Alvarez, A., Idesis, S., Girn, M., Roseman, L., Mitchell, J., Gazzaley, A. H., et al. (2026) · Human Brain Mapping · doi:10.1002/hbm.70596 · Cited by 9
“…underlying such profound long-term changes across these various psychiatric conditions, which range from alle-viation of anhedonia and apathy (Carhart-Harris et al. 2016, 2021; Goodwin et al. 2022), to reduced substance craving (Bogenschutz 2022; Johnson et al. 2017), and increased openness…”
Self-citationSind Psychedelika schnell wirksame Antidepressiva?
Gründer, G., Brand, M., Kärtner, L., Scharf, D., Schmitz, C. N., Spangemacher, M., & Mertens, L. J. (2022) · Der Nervenarzt · doi:10.1007/s00115-021-01255-1 · Cited by 8
A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history
Kramer, E. N., Reddy, K., & Shapiro, B. B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100118 · Cited by 11
Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13214 · Cited by 8
Recent advances in the psychopharmacology of major depressive disorder
Alexander, L., & Young, A. H. (2022) · BJPsych Advances · doi:10.1192/bja.2022.14 · Cited by 9
“…RCT found that two 25 mg doses of psilocybin separated by 3 weeks were non-inferior to a 6-week course of escitalopram (coupled with a 1 mg ‘ placebo-like ’ daily dose of psilocybin) as measured by scores at week 6 on the Quick Inventory of Depressive Symptomatology (QIDS-16) (Carhart-Harris 2021).”
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.